Study subjects classified according to status as carriers of c.−3383C>G PCSK9 and c.*52G>A LDLR variants and response of LDL cholesterol levels to Armolipid Plus.

The pharmacology of pcsk9 inhibitors

Alshuqayh, Salem

March 2017

Hypercholesterolemia, a condition marked by high levels of cholesterol in the blood affects over 30 ...

Anti-PCSK9 treatment: Is ultra-low LDL always good?

Noto D
Giammanco A
Barbagallo CM
Cefalu' AB
Averna M

January 2018

Anti-pcsk9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent ...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of Armolipid Plus with berberine

VALLS ZAMORA, ROSA MARIA

January 2016

Background: Armolipid Plus (AP) is a nutraceutical that contains policosanol, fermented rice with re...

Type 9 Concentrations, and LDL Cholesterol Response:

Proprotein Convertase Subtilisin/kexin
The Jupiter Trial
Paul M Ridker
Jacques Genest

September 2016

BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...

Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report

Verbeek, Rutger
Boyer, Marjorie
Boekholdt, S. Matthijs
Hovingh, G. Kees
Kastelein, John J. P.
Wareham, Nicholas
Khaw, Kay-Tee
Arsenault, Benoit J.

January 2017

Carriers of the PCSK9 (proprotein convertase subtilisin/kexin 9) R46L genetic variant (rs11591147) a...

Odds ratio of an individual being a carrier of a loss-of-function variant in one of three genes known to affect LDL-C levels: (LDLR, APOB and PCSK9) if they were classified as misaligned to their LDL-C polygenic score.

Gareth Hawkes (16871117)
Loic Yengo (3247704)
Sailaja Vedantam (131467)
Eirini Marouli (4585735)
Robin N. Beaumont (3142149)
Jessica Tyrrell (482364)
Michael N. Weedon (10953860)
Joel Hirschhorn (478480)
Timothy M. Frayling (9243710)
Andrew R. Wood (9739738)

September 2023

Odds ratio of an individual being a carrier of a loss-of-function variant in one of three genes know...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Change in PCSK9 concentrations (in percent from baseline) according to baseline PCSK9 concentrations and change in LDL cholesterol (in percent from baseline).

Heiner K. Berthold (344265)
Nabil G. Seidah (148050)
Suzanne Benjannet (395113)
Ioanna Gouni-Berthold (121150)

March 2013

Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Troutt Jason S
Konrad Robert J
Cao Guoqing

February 2011

Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
Iperen, E. van
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
Schouw, Y.T. van der
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.A.
Bobak, M.
Malyutina, S.
Pajak, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
Andrade, M. de
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
Harst, P. van der
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dorr, M.
Lerch, M.M.
Volker, U.
Volzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.C.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, R.P.E.
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.
Lifelines Cohort
ICBP Consortium
ISGC

October 2019

Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and ...

Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2

Brouwers, Martijn C. G. J.
van Greevenbroek, Marleen M. J.
Konrad, Robert J.
Troutt, Jason. S.
Schaper, Nicolaas C.
Stehouwer, Coen D. A.

May 2014

Homozygous carriers of the apolipoprotein 62 allele are at risk of type III hyperlipidaemia, but do ...

Relative change of LDL cholesterol after PCSK9 inhibitor therapy.

Michael Kühl (132789)
Christian Binner (6236801)
Joanna Jozwiak (6236804)
Julia Fischer (173836)
Jochen Hahn (6236807)
Alaeldin Addas (6236810)
Boris Dinov (6236813)
Jens Garbade (6236816)
Gerhard Hindricks (52344)
Michael Borger (5003072)

January 2019

Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...

Studies in Cholesterol Metabolism: Relationship to Statin Efficacy, Obesity and Lipoprotein Fractions

Michel R Hoenig

May 2011

Background: Low density lipoprotein cholesterol (LDL-C) predicts cardiovascular events and lowering ...

The pharmacology of pcsk9 inhibitors

Alshuqayh, Salem

March 2017

Hypercholesterolemia, a condition marked by high levels of cholesterol in the blood affects over 30 ...

Anti-PCSK9 treatment: Is ultra-low LDL always good?

Noto D
Giammanco A
Barbagallo CM
Cefalu' AB
Averna M

January 2018

Anti-pcsk9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent ...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of Armolipid Plus with berberine

VALLS ZAMORA, ROSA MARIA

January 2016

Background: Armolipid Plus (AP) is a nutraceutical that contains policosanol, fermented rice with re...

Type 9 Concentrations, and LDL Cholesterol Response:

Proprotein Convertase Subtilisin/kexin
The Jupiter Trial
Paul M Ridker
Jacques Genest

September 2016

BACKGROUND: Although statin therapy is known to in-crease concentrations of PCSK9, whether this effe...

Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report

Verbeek, Rutger
Boyer, Marjorie
Boekholdt, S. Matthijs
Hovingh, G. Kees
Kastelein, John J. P.
Wareham, Nicholas
Khaw, Kay-Tee
Arsenault, Benoit J.

January 2017

Carriers of the PCSK9 (proprotein convertase subtilisin/kexin 9) R46L genetic variant (rs11591147) a...

Odds ratio of an individual being a carrier of a loss-of-function variant in one of three genes known to affect LDL-C levels: (LDLR, APOB and PCSK9) if they were classified as misaligned to their LDL-C polygenic score.

Gareth Hawkes (16871117)
Loic Yengo (3247704)
Sailaja Vedantam (131467)
Eirini Marouli (4585735)
Robin N. Beaumont (3142149)
Jessica Tyrrell (482364)
Michael N. Weedon (10953860)
Joel Hirschhorn (478480)
Timothy M. Frayling (9243710)
Andrew R. Wood (9739738)

September 2023

Odds ratio of an individual being a carrier of a loss-of-function variant in one of three genes know...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Change in PCSK9 concentrations (in percent from baseline) according to baseline PCSK9 concentrations and change in LDL cholesterol (in percent from baseline).

Heiner K. Berthold (344265)
Nabil G. Seidah (148050)
Suzanne Benjannet (395113)
Ioanna Gouni-Berthold (121150)

March 2013

Subjects were divided approximately in tertiles: baseline PCSK9<40 ng/mL, 40 to <60 ng/mL, or ≥60...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Troutt Jason S
Konrad Robert J
Cao Guoqing

February 2011

Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
Iperen, E. van
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
Schouw, Y.T. van der
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.A.
Bobak, M.
Malyutina, S.
Pajak, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
Andrade, M. de
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
Harst, P. van der
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dorr, M.
Lerch, M.M.
Volker, U.
Volzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.C.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, R.P.E.
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.
Lifelines Cohort
ICBP Consortium
ISGC

October 2019

Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and ...

Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2

Brouwers, Martijn C. G. J.
van Greevenbroek, Marleen M. J.
Konrad, Robert J.
Troutt, Jason. S.
Schaper, Nicolaas C.
Stehouwer, Coen D. A.

May 2014

Homozygous carriers of the apolipoprotein 62 allele are at risk of type III hyperlipidaemia, but do ...

Relative change of LDL cholesterol after PCSK9 inhibitor therapy.

Michael Kühl (132789)
Christian Binner (6236801)
Joanna Jozwiak (6236804)
Julia Fischer (173836)
Jochen Hahn (6236807)
Alaeldin Addas (6236810)
Boris Dinov (6236813)
Jens Garbade (6236816)
Gerhard Hindricks (52344)
Michael Borger (5003072)

January 2019

Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be see...

Studies in Cholesterol Metabolism: Relationship to Statin Efficacy, Obesity and Lipoprotein Fractions

Michel R Hoenig

May 2011

Background: Low density lipoprotein cholesterol (LDL-C) predicts cardiovascular events and lowering ...

The pharmacology of pcsk9 inhibitors

Alshuqayh, Salem

March 2017

Hypercholesterolemia, a condition marked by high levels of cholesterol in the blood affects over 30 ...

Anti-PCSK9 treatment: Is ultra-low LDL always good?

Noto D
Giammanco A
Barbagallo CM
Cefalu' AB
Averna M

January 2018

Anti-pcsk9 (proprotein convertase subtilisin kexin 9) monoclonal antibodies (Mab) are novel, potent ...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Study subjects classified according to status as carriers of c.−3383C>G <i>PCSK9</i> and c.*52G>A <i>LDLR</i> variants and response of LDL cholesterol levels to Armolipid Plus.

Abstract

Extracted data

Related items

Related items